This inventor holds 1 USPTO granted patent. Top assignee: Valipharma. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Innovations in Oncology: The Contributions of Kai J E Krohn
Introduction
Kai J E Krohn is an innovative inventor based in Salmentaka, Finland. He has made significant contributions to the fields of genetics and oncology, particularly in the diagnosis and treatment of cutaneous T-cell lymphomas (CTCL). His work focuses on developing methods that enhance the understanding and management of this complex disease.
Latest Patents
Krohn holds a patent related to methods and means for detecting CTCL or susceptibility to CTCL. This invention provides a novel approach for diagnosing and monitoring CTCL by determining the expression of specific genes, gene fragments, or gene products. The patent also outlines methods for assessing the response to CTCL therapy and developing improved treatment options. Additionally, it includes the creation of a test kit designed to facilitate the detection of relevant genetic markers.
Career Highlights
Krohn's career is marked by his dedication to advancing medical science through innovative research. His work at Valipharma has positioned him as a key figure in the development of therapeutic strategies for CTCL. His patent reflects his commitment to improving patient outcomes through genetic insights.
Collaborations
Krohn has collaborated with notable colleagues, including Annamari Ranki and Sonja Hahtola. These partnerships have contributed to the depth and impact of his research in the field of oncology.
Conclusion
Kai J E Krohn's contributions to the field of oncology through his innovative patent demonstrate his commitment to advancing medical science. His work not only enhances the understanding of CTCL but also paves the way for improved diagnostic and therapeutic strategies.